Healthcare Industry News: Senographe
News Release - April 27, 2006
R2 Technology Announces CAD Distribution Agreement with GE HealthcareSUNNYVALE, Calif., April 27 (HSMN NewsFeed) -- R2 Technology, Inc., a leader in computer aided detection (CAD) technology for the earlier detection of breast cancer and other medical conditions, today announced a multi-year agreement with GE Healthcare, a division of the General Electric Company (NYSE: GE ). Under the agreement, GE Healthcare will distribute R2's proprietary ImageChecker® D mammography CAD system with the GE Senographe® 2000D, Senographe DS full-field digital mammography (FFDM) systems in GE's international markets outside the USA, and the new GE Senographe Essential FFDM system once commercially available.
"CAD technology is quickly becoming the standard of care in mammography screening and R2 has established itself as an industry leader. By offering an integrated solution of R2's innovative CAD technology with our high-quality and market-leading Senographe products, we can now help physicians with the earlier detection of breast cancer," said Folke Lindberg, general manager of global mammography for GE Healthcare.
"Our agreement with GE extends the global reach of our innovative CAD technology," said John Pavlidis, R2 Technology's president and chief executive officer. "The integrated solution of GE's FFDM systems customized with R2's CAD technology provides physicians worldwide with a powerful tool in the fight against breast cancer."
R2's ImageChecker was the first CAD system approved by the FDA for mammography in 1998 and R2 was the first to offer FDA-approved CAD for digital mammography in 2001, together with GE. Since 1998, the company has received multiple supplemental approvals for technological and clinical advances and owns or has exclusive worldwide rights in more than 115 issued and pending patents. To date, more than 2500 ImageChecker mammography CAD systems have been sold worldwide. Five independent prospective clinical studies* from academic and community practices showed that the use of R2's mammography CAD resulted in 6.6 percent to 19.5 percent more cancers detected.
About R2 Technology, Inc.
R2 Technology, Inc., headquartered in Sunnyvale, CA, is a recognized leader in the development and commercialization of computer aided detection (CAD), an innovative technology that assists physicians in the earlier detection of breast cancer, actionable lung nodules and other lung abnormalities. As a medical imaging company dedicated to diagnostic decision support, increasing physician productivity and preventing medical errors, R2 Technology is developing CAD systems for a variety of imaging modalities and disease states. For more information, visit www.r2tech.com or call 866-243-2533.
NOTE: ImageChecker is a registered trademark of R2 Technology, Inc.
* Studies available upon request.
Source: R2 Technology
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.